Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook

Stock Track

2024/11/07

Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.

The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.

The strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1116940554"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116940554\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116940554?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116940554","market":"hk","top_or_hot":-1,"title":"Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook","media":"Stock Track","content":"<p>Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.</p>\n\n<p>The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.</p>\n\n<p>The strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-07 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.</p>\n\n<p>The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.</p>\n\n<p>The strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"","article_id":"1116940554","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116940554","pubTimestamp":1730985023,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cytek Biosciences  surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last yea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTKB":"Cytek BioSciences"},"translate_title":"股票赛道Cytek Biosciences因2024年第三季度业绩出色、前景乐观而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":1},"content_text":"Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.\nThe company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.\nThe strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}